Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$2.35 USD
+0.06 (2.62%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.30 -0.05 (-2.13%) 7:10 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.35 USD
+0.06 (2.62%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.30 -0.05 (-2.13%) 7:10 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 687.9% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Sell Stocks for June 29th
by Zacks Equity Research
ITRG, TARA, QTNT, VNCE and APDN have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2021.
TherapeuticsMD (TXMD) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.